PO.MCB05.02 · 分子与细胞生物学

通过单一检测实现全面且精确的结构变异检测

Comprehensive & precise structural variant detection with a single assay

海报缩略图:通过单一检测实现全面且精确的结构变异检测
编号 517 展板 8 时间 4/19 02:00–05:00 区域 Section 21 主讲 John Sanborn
分会场 Mechanisms and Targets in DNA Damage Repair
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

J. Zachary Sanborn, James Durbin, Mital Bhakta, Lisa Munding

Cantata Bio, LLC, Scotts Valley, CA

摘要 Abstract

中文摘要
结构变异(SVs)日益被认为是肿瘤发生的关键驱动因素,然而由于分辨率限制和测序局限,当前技术在检测和准确表征它们方面面临困难。因此,构建完整的体细胞SV真值集的尝试常因所用测序技术在检测性能上的缺陷而受到影响,从而削弱了这些真值集在对替代技术和/或SV检出工具进行基准评估时的实用性。为此,美国国家标准与技术研究院(NIST)针对体细胞SV检测开展了一项深度基准实验,采用16种全基因组测序技术全面表征了一例胰腺导管癌(PDAC,标记为HG008T)的结构变化,并使用多种针对特定数据类型的SV检出工具进行分析。NIST发布了其Benchmark SV检出集,该结果整合并人工审校了所有分析物的检出结果。借助这些基准数据,我们检验了单独使用Dovetail的LinkPrep化学方法、结合开源和专有SV检出工具,重现NIST Benchmark检出集的能力。 针对HG008T细胞系样本构建了Dovetail LinkPrep文库,并测序至约55x基因组覆盖度。测序数据用bwa比对至hg38,并通过运行标准的、基于HiC的SV检出工具HiC-Breakfinder,以及Dovetail Genomics开发的新型SV检出工具Dovetail Precise(DP)生成SV检出结果。这些检出集分别与NIST Benchmark检出集进行比较,以评估它们在基于SV类型和大小的各类别中的性能。 在NIST Benchmark检出集共109个SV中,HiC-Breakfinder和DP分别检测到19个(18%)和97个(92%)SV。HiC-Breakfinder检测SV的能力仅限于易位(12个中的8个,67%)和大于2 Mb的大型染色体内SV(11个中的10个,91%),而无法发现任何小于2 Mb的染色体内SV。相比之下,DP检测到了所有易位(12个中的12个,100%)、同样数量的大型染色体内SV(11个中的10个,91%),以及大多数较小的染色体内SV(85个中的75个,88%),最小可达47 bp。此外,HiC-Breakfinder与NIST Benchmark SV之间断裂端位置的差异介于1,636 bp至189 kb之间,而超过96%的DP检出结果(97个中的94个)达到了碱基级精度。 Dovetail的LinkPrep化学方法结合Dovetail Precise(DP)检出工具检测到NIST Benchmark检出集中92%的体细胞结构变异(SVs),包括小至47 bp的小变异,在所有SV类型和大小上均显著优于HiC-Breakfinder。这种高分辨率SV检测使得通过单一检测即可实现更全面的癌症基因组表征,并支持更准确的诊断和靶向治疗开发。
查看英文原文 English abstract
Structural variants (SVs) are increasingly recognized as key drivers of tumorigenesis, yet current technologies struggle to detect and accurately characterize them due to resolution limitations and sequencing constraints. As a result, attempts to produce complete somatic SV truth sets often suffer due to the gaps in detection performance of the sequencing technology utilized, impacting the truth sets' usefulness for benchmarking alternative technologies and/or SV callers. To this end, the National Institute of Standards & Technology (NIST) performed a deep benchmarking experiment for somatic SV detection, fully characterizing the structural changes of a pancreatic ductal carcinoma (PDAC, labeled HG008T) across 16 whole genome sequencing technologies and analyzing with multiple datatype-specific SV callers. NIST has published its Benchmark SV callset that is the result of integrating and manually curating calls from all analytes. With this benchmarking data, we tested the capability of Dovetail's LinkPrep chemistry alone to reproduce the NIST Benchmark callset using both open source and proprietary SV callers. Dovetail LinkPrep libraries were generated for the HG008T cell line sample and sequenced to approximately 55x genomic coverage. Sequencing data was aligned to hg38 with bwa and SV calls generated by running a standard, HiC-based SV caller, HiC-Breakfinder, and Dovetail Precise (DP), a new SV caller developed by Dovetail Genomics. These callsets were separately compared to the NIST Benchmark callset to assess their performance in categories based on SV type and size. Of the 109 total SVs in the NIST Benchmark callset, HiC-Breakfinder and DP detected 19 (18%) and 97 (92%) SVs, respectively. HiC-Breakfinder's ability to detect SVs was limited to translocations (8 of 12, 67%) and large intra-chromosomal SVs greater than 2 Mb in size (10 of 11, 91%), while unable to find any intra-chromosomal SV smaller than 2 Mb. In contrast, DP detected all translocations (12 of 12, 100%), the same number of large intra-chromosomal SVs (10 of 11, 91%), and the majority of smaller intra-chromosomal SVs (75 of 85, 88%) down to 47 bp in size. Furthermore, the difference in breakend locations between HiC-Breakfinder and the NIST Benchmark SVs ranged from 1,636 bp to 189 kb, while over 96% of DP calls (94 of 97) achieved base-level precision. Dovetail's LinkPrep chemistry with the Dovetail Precise (DP) caller detected 92% of somatic structural variants (SVs) in the NIST Benchmark callset, including small variants down to 47 bp, strongly outperforming HiC-Breakfinder across all SV types and sizes. This high-resolution SV detection enables more comprehensive cancer genome characterization from a single assay and supports more accurate diagnostics and targeted therapy development.
利益披露 Disclosure
J. Z. Sanborn, Cantata Bio, LLC Employment, Stock. J. Durbin, Cantata Bio, LLC Employment, Stock Option. M. Bhakta, Cantata Bio, LLC Employment, Stock Option. L. Munding, Cantata Bio, LLC Employment, Stock Option.

← 返回 AACR 2026 检索